148 related articles for article (PubMed ID: 23331449)
1. Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.
Majumdar SR; Lier DA; McAlister FA; Rowe BH; Siminoski K; Hanley DA; Russell AS; Johnson JA
Am J Med; 2013 Feb; 126(2):169.e9-17. PubMed ID: 23331449
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial.
Majumdar SR; Lier DA; Leslie WD
J Clin Endocrinol Metab; 2013 May; 98(5):1991-2000. PubMed ID: 23596140
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
[TBL] [Abstract][Full Text] [Related]
4. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
[TBL] [Abstract][Full Text] [Related]
5. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Goeree R; Blackhouse G; Adachi J
Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
[TBL] [Abstract][Full Text] [Related]
8. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Osteoporosis Interventions to Improve Quality of Care After Upper Extremity Fracture: Results From a Randomized Trial (C-STOP Trial).
Majumdar SR; Lier DA; McAlister FA; Johnson JA; Rowe BH; Beaupre LA
J Bone Miner Res; 2019 Jul; 34(7):1220-1228. PubMed ID: 30779861
[TBL] [Abstract][Full Text] [Related]
12. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Jansen JP; Gaugris S; Bergman G; Sen SS
Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.
Hiligsmann M; Ethgen O; Bruyère O; Richy F; Gathon HJ; Reginster JY
Value Health; 2009; 12(5):687-96. PubMed ID: 19508659
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Meadows ES; Klein R; Rousculp MD; Smolen L; Ohsfeldt RL; Johnston JA
BMC Womens Health; 2007 Apr; 7():6. PubMed ID: 17439652
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial.
Majumdar SR; Lier DA; Beaupre LA; Hanley DA; Maksymowych WP; Juby AG; Bell NR; Morrish DW
Arch Intern Med; 2009 Jan; 169(1):25-31. PubMed ID: 19139320
[TBL] [Abstract][Full Text] [Related]
17. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
[TBL] [Abstract][Full Text] [Related]
19. [The necessity of cost-effectiveness analysis in osteoporosis].
Lamy O; Krieg MA
Rev Med Suisse; 2007 Jun; 3(115):1521-5. PubMed ID: 17682796
[TBL] [Abstract][Full Text] [Related]
20. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Berto P; Maggi S; Noale M; Lopatriello S
Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
